Download the full white paper to explore how IFB strategies are the evolution of mammalian cell culture manufacturing.

Biomanufacturers are under constant pressure to produce more with the assets they already have. In many facilities, the traditional path to increased output has meant expanding footprint, adding infrastructure, or building new capacity altogether.

But that model is shifting. Across the industry, intensified fed-batch (IFB) strategies are being actively evaluated as manufacturers look for more efficient ways to scale production, improve facility utilization, and strengthen the long-term economics of large-scale biologics manufacturing. What was once considered an optimization tactic is increasingly being evaluated as a core platform strategy.

That shift is exactly what prompted our latest flagship white paper.

The Evolution of Mammalian Cell Culture Manufacturing, developed by Project Farma experts with direct client project experience, takes a practical look at how IFB approaches are being implemented today and what they mean for the future of manufacturing operations.

In this white paper, readers will explore:

• Where IFB strategies are delivering measurable gains in productivity and facility utilization
• The operational and infrastructure implications of adopting IFB at scale
• How upstream productivity improvements influence downstream processing requirements
• Key factors to evaluate when designing or evolving mammalian cell culture platforms
• Why IFB is becoming a strategic consideration for new and existing manufacturing facilities

For organizations evaluating how to expand output without expanding footprint, this conversation is becoming increasingly relevant.